Hutchison Chi-Med eyes $500m HK listing
Biopharmaceutical company Hutchison China MediTech (Chi-Med) is planning a Hong Kong IPO of around $500m, having filed a draft prospectus with the city’s stock exchange on Monday.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts